Hereditary transthyretin-mediated amyloidosis with polyneuropathy

Clinical trials for Hereditary transthyretin-mediated amyloidosis with polyneuropathy explained in plain language.

Never miss a new study

Get alerted when new Hereditary transthyretin-mediated amyloidosis with polyneuropathy trials appear

Sign up with your email to follow new studies for Hereditary transthyretin-mediated amyloidosis with polyneuropathy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New shot every 6 months could slow rare nerve disease

Disease control Recruiting now

This Phase 3 trial tests a new drug called nucresiran in 125 people with a rare inherited condition that damages nerves (hATTR-PN). The drug is given as a shot under the skin every 6 months and aims to slow nerve damage and improve quality of life. Researchers will compare it to …

Matched conditions: HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY

Phase 3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control

Last updated Sep 17, 2026 00:00 UTC

Hereditary transthyretin-mediated amyloidosis with polyneuropathy

Get alerted when new Hereditary transthyretin-mediated amyloidosis with polyneuropathy trials appear

New shot every 6 months could slow rare nerve disease